FDA Approves SPEVIGO for Generalized Pustular Psoriasis Flares

TUESDAY, Sept. 6, 2022 -- The U.S. Food and Drug Administration has approved SPEVIGO (spesolimab-sbzo) as the first treatment option for generalized pustular psoriasis (GPP) flares in adults. SPEVIGO is a novel, selective antibody infusion that...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news